PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Samsara Inc. (IOT)
33.600.80 (-2.33%)
33.44 - 34.57
31.40 - 61.90
7.61M / 5.87M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.34%
Revenue growth similar to BRZE's 7.69%. Walter Schloss would see if both companies share industry tailwinds.
9.70%
Gross profit growth similar to BRZE's 9.98%. Walter Schloss would assume both firms track common industry trends.
21.49%
EBIT growth above 1.5x BRZE's 0.67%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
21.49%
Operating income growth above 1.5x BRZE's 0.67%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
24.07%
Net income growth above 1.5x BRZE's 3.01%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
23.00%
EPS growth above 1.5x BRZE's 6.06%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
23.00%
Diluted EPS growth above 1.5x BRZE's 6.06%. David Dodd would see if there's a robust moat protecting these shareholder gains.
1.07%
Share count expansion well above BRZE's 0.72%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.07%
Diluted share count expanding well above BRZE's 0.72%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
54.00%
OCF growth at 50-75% of BRZE's 88.57%. Martin Whitman would question if the firm lags in monetizing sales effectively.
80.96%
FCF growth 1.25-1.5x BRZE's 68.38%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
-4.16%
Negative 10Y revenue/share CAGR while BRZE stands at 190.60%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-4.16%
Negative 5Y CAGR while BRZE stands at 190.60%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-4.16%
Negative 3Y CAGR while BRZE stands at 190.60%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
113.23%
10Y OCF/share CAGR above 1.5x BRZE's 68.58%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
113.23%
5Y OCF/share CAGR above 1.5x BRZE's 68.58%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
113.23%
3Y OCF/share CAGR above 1.5x BRZE's 68.58%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
35.56%
Positive 10Y CAGR while BRZE is negative. John Neff might see a substantial advantage in bottom-line trajectory.
35.56%
Positive 5Y CAGR while BRZE is negative. John Neff might view this as a strong mid-term relative advantage.
35.56%
Positive short-term CAGR while BRZE is negative. John Neff would see a clear advantage in near-term profit trajectory.
169.40%
Equity/share CAGR of 169.40% while BRZE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
169.40%
Equity/share CAGR of 169.40% while BRZE is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
169.40%
Equity/share CAGR of 169.40% while BRZE is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.19%
Firm’s AR is declining while BRZE shows 1.71%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
24.51%
Inventory growth of 24.51% while BRZE is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
2.66%
Asset growth at 50-75% of BRZE's 5.02%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
0.48%
Positive BV/share change while BRZE is negative. John Neff sees a clear edge over a competitor losing equity.
-1.91%
We’re deleveraging while BRZE stands at 76.48%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.92%
Our R&D shrinks while BRZE invests at 2.54%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.63%
We cut SG&A while BRZE invests at 11.69%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.